Thomas Shrader, PhD, CFA

Contact Us

Thomas Shrader, PhD, CFA, is a Managing Director and Healthcare Analyst at BTIG. He provides coverage of the biotechnology sector, with a focus on large and smidcap companies. Prior to BTIG, Mr. Shrader was the Vice President of Strategy and Communications at Intrexon Corporation. Previously, he was a Biotechnology Research Analyst at Stifel. Earlier in his career, Mr. Shrader was on the Biochemistry Faculty at the Albert Einstein College of Medicine. He earned a BA from The Johns Hopkins University, a PhD from Yale University and was a Helen Hay Whitney Fellow at the Massachusetts Institute of Technology.


Coverage Area

Company Ticker
Gain Therapeutics, Inc. GANX
Biogen, Inc. BIIB
Denali Therapeutics Inc. DNLI
Esperion Therapeutics, Inc. ESPR
Verona Pharma plc VRNA
Alector Inc. ALEC
Stoke Therapeutics, Inc. STOK
BridgeBio Pharma, Inc. BBIO
INmune Bio Inc. INMB
Aldeyra Therapeutics ALDX
Silence Therapeutics SLN
Seelos Therapeutics, Inc. SEEL
Pliant Therapeutics PLRX
Celularity CELU
COMPASS Pathways plc CMPS
Athira Pharma ATHA
Acumen Pharmaceuticals ABOS
Vaxcyte, Inc. PCVX
Biohaven Ltd. BHVN
Coya Therapeutics, Inc. COYA
ProMIS Neurosciences Inc. PMN